## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-122. (cancelled)

123. (new) A compound of the formula:



(1)

wherein:

$R^N$ is independently $C_{1-7}$alkyl;

$X^1$ is independently -I, -Br, or -Cl;

$X^2$ is independently -I, -Br, or -Cl;

the group $-N(CH_2CH_2X^1)(CH_2CH_2X^2)$ is independently attached at the 2-position or at the 4-position;

each $R^G$ is independently -H or an ester substituent;

n is independently an integer from 0 to 4;

each $R^P$, if present, is independently a phenyl substituent;

m is independently an integer from 0 to 4;

each $R^M$, if present, is independently a mustard substituent;

and pharmaceutically acceptable salts, solvates, amides, and esters thereof.

124. (new) A compound according to claim 123, wherein $R^N$ is independently unsubstituted aliphatic $C_{1-7}$alkyl.

125. (new) A compound according to claim 123, wherein $R^N$ is independently unsubstituted aliphatic $C_{1-4}$alkyl.

126. (new) A compound according to claim 123, wherein $R^N$ is independently -Me, -Et, -nPr, -iPr, -allyl, -nBu, -sBu, -iBu, or -tBu.

127. (new) A compound according to claim 123, wherein $R^N$ is independently -Me or -Et.

128. (new) A compound according to claim 123, wherein $R^N$ is independently -Me.

129. (new) A compound according to claim 123, wherein each of $X^1$ and $X^2$ is independently -I.

130. (new) A compound according to claim 123, wherein each of $X^1$ and $X^2$ is independently -Br.

131. (new) A compound according to claim 123, wherein each of $X^1$ and $X^2$ is independently -Cl.

132. (new) A compound according to claim 123, wherein

$R^N$ is independently $C_{1-4}$alkyl; and,

each X is independently -Cl, -Br or -I.

133. (new) A compound according to claim 123, wherein

$R^N$ is independently -Me; and,

each X is independently -Cl, -Br or -I.

134. (new) A compound according to claim 123, wherein

$R^N$ is independently $C_{1-4}$alkyl; and,

each X is independently -I.

135. (new) A compound according to claim 123, wherein

$R^N$ is independently -Et or -Me; and,

each X is independently -I.

136. (new) A compound according to claim 123, wherein

$R^N$ is independently -Me; and,

each X is independently -I.

137. (new) A compound according to claim 123, wherein the group

$-N(CH_2CH_2X^1)(CH_2CH_2X^2)$ is independently attached at the 4-position.

138. (new) A compound according to claim 123, wherein

$R^N$ is independently $C_{1-4}$alkyl;

each X is independently -Cl, -Br or -I; and,

the group $-N(CH_2CH_2X)_2$ is independently attached at the 4-position.

139. (new) A compound according to claim 123, wherein

$R^N$ is independently -Me;

each X is independently -Cl, -Br or -I; and,

the group $-N(CH_2CH_2X)_2$ is independently attached at the 4-position.

140. (new) A compound according to claim 123, wherein

$R^N$ is independently $C_{1-4}$alkyl;

each X is independently -I; and,

the group $-N(CH_2CH_2X)_2$ is independently attached at the 4-position.

141. (new) A compound according to claim 123, wherein

$R^N$ is independently -Et or -Me;

each X is independently -I; and,

the group $-N(CH_2CH_2X)_2$ is independently attached at the 4-position.

142. (new) A compound according to claim 123, wherein

$R^N$ is independently -Me;

each X is independently -I; and,

the group $-N(CH_2CH_2X)_2$ is independently attached at the 4-position.

143. (new) A compound according to claim 123, wherein n is 0, 1, or 2.

144. (new) A compound according to claim 138, wherein n is 0.

145. (new) A compound according to claim 123, wherein each $R^P$, if present, is independently halo, $C_{1-4}$alkyl, nitro, or cyano.

146. (new) A compound according to claim 123, wherein each $R^P$, if present, is independently:

-F, -Cl, -Br, -I, -Me, -Et, -nPr, -iPr, -nBu, -sBu, -iBu, -tBu, $-NO_2$, or -CN.

147. (new) A compound according to claim 123, wherein each $R^P$, if present, is independently -F, -Cl, -Br, or -I.

148. (new) A compound according to claim 123, wherein m is 0, 1, or 2.

149. (new) A compound according to claim 138, wherein m is 0.

150. (new) A compound according to claim 144, wherein m is 0.

151. (new) A compound according to claim 123, wherein each $R^M$, if present, is independently selected from: $C_{1-4}$alkyl; $C_{1-4}$alkoxy; amino; halo; $C_{1-4}$alkylthio; acyl; ester; amido; cyano; nitro; and, $C_{5-6}$aryl.

152. (new) A compound according to claim 123, wherein each $R^M$, if present, is independently selected from:

-Me, -Et, -nPr, -iPr, -nBu, -sBu, -iBu, -tBu;

$-CF_3$, $-CH_2F$, $-CH_2CF_3$, $-CH_2CH_2F$; $-CF_2CF_3$;

-OMe, -OEt, -O-nPr, -O-iPr, -O-nBu, -O-sBu, -O-iBu, -O-tBu;

$-OCF_3$, $-OCH_2F$, $-OCH_2CF_3$, $-OCH_2CH_2F$; $-OCF_2CF_3$;

$-NH_2$, $-NMe_2$, $-NEt_2$, $-N(nPr)_2$, $-N(iPr)_2$,

-F, -Cl, -Br, -I;

-SMe, -SEt;

-C(=O)Me;

-C(=O)OMe, -C(=O)OEt;

$-CONH_2$, -CONHMe;

-CN;

$-NO_2$; and,

-Ph.

153. (new) A compound according to claim 123, wherein each $R^M$, if present, is independently selected from:

-Me, -Et, $-CF_3$, -OMe, -OEt, $-NH_2$, and $-NMe_2$.

154. (new) A compound according to claim 123, wherein each $R^G$ is independently -H.

155. (new) A compound according to claim 123, wherein each $R^G$ is independently -H, unsubstituted $C_{1-7}$alkyl, substituted $C_{1-7}$alkyl, or silyl.

156. (new) A compound according to claim 123, wherein each $R^G$ is independently -H; unsubstituted $C_{1-4}$alkyl; $C_{1-4}$alkyl substituted with one or more groups selected from optionally substituted $C_{5-20}$aryl, $C_{1-7}$alkoxy, $C_{1-7}$alkylthio, and acyloxy; or $-SiR^S_3$, wherein each $R^S$ is independently -H or $C_{1-4}$alkyl.

157. (new) A compound according to claim 123, wherein each $R^G$ is independently -H; -Me; -Et; -nPr; -iPr; -allyl; -nBu; -sBu; -iBu; -tBu; $C_{1-4}$alkyl substituted with one or more groups selected from optionally substituted phenyl, methoxy, methylthio, acetoxy, and benzoyloxy; $-Si(Me)_3$; $-Si(Et)_3$; $-Si(iPr)_3$; $-Si(tBu)(CH_3)_2$; or $-Si(tBu)_3$.

158. (new) A compound according to claim 123, wherein each $R^G$ is independently (1) t-butyl, (2) allyl, (3) tri-isopropylsilyl, (4) acetoxymethyl, (5) methoxymethyl, (6) methylthiomethyl, (7) p-methoxyphenylmethyl, (8) bis(o-nitrophenyl)methyl, (9) benzyl, or (10) diphenylmethyl.

159. (new) A compound according to claim 123, wherein each $R^G$ is independently (1) t-butyl, (2) allyl, or (3) tri-isopropylsilyl.

160. (new) A compound according to claim 123, wherein each $R^G$ is independently (1) allyl.

161. (new) A compound selected from compounds of the following formula (P-1), and pharmaceutically acceptable salts, solvates, amides, and esters thereof:



162. (new) A compound selected from compounds of the following formula (P-2), and pharmaceutically acceptable salts, solvates, amides, and esters thereof:




163. (new) A compound selected from compounds of the following formula (P-3), and pharmaceutically acceptable salts, solvates, amides, and esters thereof:




164. (new) A composition comprising a compound according to claim 123, and a pharmaceutically acceptable carrier.

165. (new) A kit comprising:

(a) a compound according to claim 123; and

(b) instructions for use.

166. (new) A kit comprising:

(a) a compound according to claim 123;

(b) an antibody or fragment thereof conjugated or fused to a carboxypeptidase enzyme; and,

(c) instructions for use.

167. (new) A kit comprising:

(a) a compound according to claim 123;

(b) a nucleic acid encoding a carboxypeptidase enzyme; and,

(c) instructions for use.

168. (new) A method of (a) regulating proliferation of a cell; (b) inhibiting cell cycle progression of a cell; (c) promoting apoptosis of a cell; or (d) a combination of one or more of these, *in vitro* or *in vivo,* comprising contacting the cell with an effective amount of a compound according to claim 123.

169. (new) A method of treatment of a proliferative condition comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to claim 123.

170. (new) A method of treatment of cancer comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to claim 123.

171. (new) A method of (a) regulating proliferation of a cell; (b) inhibiting cell cycle progression of a cell; (c) promoting apoptosis of a cell; or (d) a combination of one or more of these, *in vitro* or *in vivo,* comprising contacting the cell with a therapeutically-effective amount of a compound according to claim 123, in the presence of a carboxypeptidase enzyme.

172. (new) A method of treatment of a proliferative condition comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to claim 123, in the presence of a carboxypeptidase enzyme.

173. (new) A method of treatment of cancer comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to claim 123, in the presence of a carboxypeptidase enzyme.

174. (new) A method of (a) regulating proliferation of a cell; (b) inhibiting cell cycle progression of a cell; (c) promoting apoptosis of a cell; or (d) a combination of one or more of these, *in vitro* or *in vivo,* comprising:

(i) contacting the cell with an antibody or fragment thereof conjugated or fused to a carboxypeptidase enzyme; and,

(ii) contacting the cell with a therapeutically-effective amount of a compound according to claim 123.

175. (new) A method of treatment of a proliferative condition, comprising administering to a subject in need of treatment:

(i) an antibody or fragment thereof conjugated or fused to a carboxypeptidase enzyme; and,

(ii) contacting the cell with a therapeutically-effective amount of a compound according to claim 123.

176. (new) A method of treatment of cancer, comprising administering to a subject in need of treatment:

(i) an antibody or fragment thereof conjugated or fused to a carboxypeptidase enzyme; and,

(ii) contacting the cell with a therapeutically-effective amount of a compound according to claim 123.

177. (new) A method of (a) regulating proliferation of a cell; (b) inhibiting cell cycle progression of a cell; (c) promoting apoptosis of a cell; or (d) a combination of one or more of these, *in vitro* or *in vivo,* comprising:

(i) contacting the cell with a nucleic acid encoding a carboxypeptidase enzyme; and,

(ii) contacting the cell with a therapeutically-effective amount of a compound according to claim 123.

178. (new) A method of treatment of a proliferative condition, comprising administering to a subject in need of treatment:

(i) a nucleic acid encoding a carboxypeptidase enzyme; and,

(ii) a therapeutically-effective amount of a compound according to claim 123.

179. (new) A method of treatment of cancer, comprising administering to a subject in need of treatment:

(i) a nucleic acid encoding a carboxypeptidase enzyme; and,

(ii) a therapeutically-effective amount of a compound according to claim 123.